Cowen restated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC) in a research note issued to investors on Monday, AnalystRatings.com reports.

Other equities analysts also recently issued reports about the stock. ValuEngine upgraded shares of Blueprint Medicines from a buy rating to a strong-buy rating in a report on Tuesday, June 4th. Goldman Sachs Group reiterated a buy rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Thursday, May 23rd. Zacks Investment Research downgraded shares of Blueprint Medicines from a buy rating to a sell rating and set a $94.00 price objective on the stock. in a report on Wednesday, August 7th. Canaccord Genuity upped their price objective on shares of Blueprint Medicines from $105.00 to $120.00 and gave the company a buy rating in a report on Friday, August 2nd. Finally, Piper Jaffray Companies began coverage on shares of Blueprint Medicines in a report on Thursday, August 29th. They set a neutral rating and a $85.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $107.60.

Shares of Blueprint Medicines stock opened at $79.00 on Monday. The company has a market capitalization of $3.59 billion, a PE ratio of -14.66 and a beta of 1.64. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.52 and a current ratio of 7.52. The company has a 50-day simple moving average of $84.83 and a two-hundred day simple moving average of $84.70. Blueprint Medicines has a one year low of $44.58 and a one year high of $102.98.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($2.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.92) by ($0.12). The firm had revenue of $5.11 million during the quarter, compared to the consensus estimate of $1.39 million. Blueprint Medicines had a negative return on equity of 73.73% and a negative net margin of 4,268.74%. The business’s revenue for the quarter was down 87.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.62) earnings per share. On average, equities analysts predict that Blueprint Medicines will post -8.44 earnings per share for the current fiscal year.

In related news, insider Ariel Hurley sold 1,405 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $98.22, for a total value of $137,999.10. Following the sale, the insider now owns 830 shares in the company, valued at $81,522.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Alexis Borisy sold 21,818 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $92.01, for a total value of $2,007,474.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 106,155 shares of company stock worth $9,511,402. Corporate insiders own 4.02% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC boosted its position in Blueprint Medicines by 5.3% in the first quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock valued at $555,491,000 after buying an additional 346,738 shares during the last quarter. Vanguard Group Inc. boosted its position in Blueprint Medicines by 8.1% in the second quarter. Vanguard Group Inc. now owns 4,281,362 shares of the biotechnology company’s stock valued at $403,861,000 after buying an additional 321,857 shares during the last quarter. BlackRock Inc. boosted its position in Blueprint Medicines by 20.9% in the second quarter. BlackRock Inc. now owns 4,109,222 shares of the biotechnology company’s stock valued at $387,621,000 after buying an additional 710,147 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Blueprint Medicines by 9.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,681,291 shares of the biotechnology company’s stock valued at $347,256,000 after buying an additional 305,682 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Blueprint Medicines by 19,169.3% in the second quarter. Invesco Ltd. now owns 1,801,102 shares of the biotechnology company’s stock valued at $169,897,000 after buying an additional 1,791,755 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

See Also: Momentum Indicators

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.